Demodex Blepharitis

NEW YORK — Reimbursement and pipeline products, as well as educating patients and doctors about Demodex blepharitis, remain priorities for Tarsus Pharmaceuticals in the wake of Xdemvy’s launch, a company executive said at Vision Expo East.

Tarsus Pharmaceuticals has launched a campaign for Xdemvy to raise consumer awareness about Demodex blepharitis, according to a press release.

There are two areas I am really excited about specifically in the areas of lid margin disease and dry eye disease.

In dry eye care, 2023 was a year of substantial changes, and ophthalmologists and their patients have welcomed more treatment options that bring relief.

Wow! That was quick. Another year has come and gone, the pages of the calendar flying by like one of those old cartoon flip chart things.

There has certainly been a whole bunch of new stuff around the dry eye disease ranch, hasn’t there?

Tarsus Pharmaceuticals has announced positive topline results from the Ersa phase 2a trial evaluating TP-03 for treatment of meibomian gland disease in patients with Demodex mites, with significant improvements reported in two key measures.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Aziz Mottiwala of Tarsus Pharmaceuticals discusses Xdemvy for the treatment of Demodex blepharitis.

Well now, it seems as though I ruffled more than a few feathers with my annual anti-inflammatory review last month.

We have all seen the chronic blepharitis patient that has attempted numerous unsuccessful treatment regimens and has visited numerous eye doctors looking for some relief. Interestingly, the cause of their chronic blepharitis might be secondary to Demodex infestation.